Viewing Study NCT02734160

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:16 AM
Ignite Modification Date: 2026-02-22 @ 6:44 PM
Study NCT ID: NCT02734160
Status: COMPLETED
Last Update Posted: 2019-08-05
First Post: 2016-04-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Sponsor: Eli Lilly and Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Pancreatic Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None immunotherapy View
None check point inhibitors View
None transforming growth factor (TGF)-beta R1 kinase inhibitor View